Company Overview
Snapshot
Founded in February 2019 by Oded Grinstein and David Delouya, Simplivia Healthcare operates with 51–200 employees. The company was acquired by FIMI Opportunity Funds in May 2019.
Business overview
Simplivia Healthcare specializes in developing and manufacturing high-quality drug-delivery solutions designed to enhance the safety of healthcare professionals. The company's core products, Tevadaptor and Chemfort, utilize its patented Toxi-Guard system to facilitate pressure equalization during use, preventing hazardous drug vapors from escaping and airborne contaminants from entering drug vials. Simplivia Healthcare serves the healthcare industry, operating within the Health Tech & Life Sciences sector, specifically focusing on Pharma & Medical Biotechnology and Drug Delivery.
Strategic signal
In January 2021, Simplivia Healthcare acquired Novamed, a diagnostics company. This strategic acquisition indicates Simplivia's intent to expand its product portfolio beyond drug-delivery solutions, signaling a move into broader medical diagnostics and potentially strengthening its market position in the health tech and life sciences sector.
Company Intelligence Q&A
- When was Simplivia Healthcare acquired?
- Simplivia Healthcare was acquired by FIMI Opportunity Funds in May 2019.
- What was the origin of Simplivia Healthcare's Tevadaptor product?
- Tevadaptor was formerly a business unit within Teva Pharmaceutical Industries before Simplivia Healthcare incorporated it following the acquisition by FIMI Opportunity Funds in May 2019.
- Which company distributes Simplivia Healthcare's products in the U.S.?
- In the U.S., Simplivia Healthcare's products are exclusively distributed by B. Braun under the brand name OnGuard.
- What was a key strategic move made by Simplivia Healthcare in January 2021?
- In January 2021, Simplivia Healthcare acquired the diagnostics company Novamed.
- What is the primary function of Simplivia Healthcare's Toxi-Guard system?
- Simplivia Healthcare's patented Toxi-Guard system, integrated into its Tevadaptor and Chemfort products, allows for pressure equalization during use, preventing the escape of hazardous drug vapors and the entry of airborne contaminants during drug reconstitution and administration.